Pamela N. Munster

Pilot Study of Pancreatic Cancer Screening

Proportion of participants with an abnormal MRI finding will be reported as an event. An estimated event rate of 19% in participants with a strong family history (FH) of pancreatic cancer and 10% in those participants without a st...

Recruiting

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor P...

Will be defined as the proportion of participants randomized to that arm whose status is stable disease (SD) or better (complete response (CR), partial response (PR)). The observed ORR will be compared to the respective null (inef...

Recruiting

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous R...

ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed...

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Adv...

Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline

Recruiting

Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...

A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related

Recruiting

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Hom...

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ...

Recruiting

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy

Recruiting

A Study of SGN-STNV in Advanced Solid Tumors

To be summarized using descriptive statistics

Recruiting

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Sol...

Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose

Recruiting

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK ...

Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)

Recruiting